Kane Biotech Expands Previously-Announced Single Largest Order of bluestem™ Products
Major Retailer Orders Additional Inventory in Anticipation of High Demand
WINNIPEG, Manitoba, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE, OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”), is pleased to announce that it has secured an additional purchase order for bluestem™ products, from the North American pet retail chain that recently purchased the largest order in Kane Biotech’s history. In anticipation of heightened bluestem™ brand awareness through Kane’s marketing efforts and campaigning for February’s Pet Dental Health month, the retailer’s supplemental order is intended to secure backup inventory.
Kane Biotech will be putting a number of marketing initiatives in place in collaboration with the retailer for the February product launch, which also coincides with Pet Dental Health month. So far, over 1500 of the retail chain’s employees have completed the online bluestem™ oral care training, which provides in-store personnel a greater understanding of the importance of pet oral care. The training will help employees and other brand ambassadors guide customers towards the bluestem™ products that best fit their pet’s needs, as well as their lifestyle.
As previously announced for Pet Dental Health month, Kane Biotech is also launching a comprehensive in-store and digital marketing campaign to increase sales and raise awareness of the importance of oral care for pets. As part of this strategy, Kane will launch a highly-targeted YouTube ad campaign, expected to be broadcast to more than five million consumers, starting in February’s Pet Dental Health month and continuing throughout 2019. The YouTube advertising campaign can be found on the following link: https://youtu.be/ZBDaXwaATGY
bluestem™ is the only pet oral care line of products that contain coactiv+ technology - scientifically developed to break down biofilm where harmful bacteria multiply. bluestem has been proven to help reduce tartar without brushing by up to 25.4%. According to the American Veterinary Dental Society, 80% of dogs and 70% of cats will suffer from dental problems by the age of 3. bluestem oral care products contain 100% food-grade ingredients that are approved by Health Canada’s VHP program, as well as follow AAFCO guidelines. bluestem’s food-grade ingredients are alcohol-free, xylitol-free, chlorhexidine-free, and sugar-free.
In a Good Clinical Practice Efficacy study, sixty dogs had their teeth cleaned and their calculus measured. Half of the dogs were given bluestem™-treated water and the other half were given regular water. After 84 consecutive days of using bluestem™-treated water, the calculus score for the treated dogs was 25.4% lower than the control group. In a controlled Good Scientific Practice (GSP) study, the safety of the bluestem™ water additive was tested over 30 days with some dogs receiving 5 times the recommended dose. After 30 days, the test revealed no evidence of adverse effects related to the consumption of the water additive.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991 firstname.lastname@example.org
Vice President, Sales and Business Development
Kane Biotech Inc.
+1 (204) 914-5089 email@example.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
These risks and uncertainties should be considered carefully undue reliance should not be placed on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot provide assurance that actual results will be consistent with these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement.
Released January 30, 2019